Temperature Controlled Logistics Market Report
Optimizing the Path from Lab to Patient
Add bookmark
As fresh trends force new demands upon the pharma supply chain, shippers must keep building on progress made thus far within temperature controlled logistics to avoid costly mistakes, according to a new deep-dive study by Pharma Logistics IQ
Statistics are showing that the pharma industry is indeed improving its management of cold chain costs – with this year’s spending on temperature controlled logistics slightly cooling in comparison to that in 2016.
The global pharmaceutical cold chain logistics industry is valued at $13.4bn
Market research
Pharma Logistics IQ presents the findings of its 2017 Temperature Controlled Logistics Report, which examines the weak points in the chain and strategies to unlock new efficiencies. Expert analysis provided by David Kim of Kite Pharma’s supply chain logistics division.
In Q3 of 2017, Pharma Logistics IQ hosted an online survey to assess current perceptions on how the cold chain industry is likely to evolve over the next few years. The survey gathered responses from 150 of the many stakeholders in the cold chain community. Companies featuring in our international respondent base include the likes of:
- Eli Lilly and Company
- Astellas Pharma Inc.
- GSK
- Hoffmann-La Roche Ltd.
- Ministry of Health Saudi Arabia
- Getz Pharma
- P&G
- National Pharmaceutical Regulatory Division - Malaysia
- EHEALTH AFRICA
- UPS
- Parexel
- Johnson & Johnson Ltd
- KPMG
Download your copy of the report today.
